Popular Articles

Micromet Presents Update At ASCO 2009 On A Phase 1b Combination Study Of Adecatumumab And Docetaxel
Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, presented data from a clinical trial investigating its anti-EpCAM human antibody adecatumumab (MT201) in combination with the chemotherapeutic docetaxel in patients with metastatic breast cancer (MBC) at the annual meeting of the American Society of Clinical Oncology (ASCO) held in Orlando, Florida, USA(1).
drugs without prescription
Calif. Senate Advances Bill To Ban Health Insurance 'Gender Rating'
The California Senate last week approved a bill (S.B. 54) that would prohibit health insurance companies from charging different rates for individual insurance policies based on gender, the San Francisco Chronicle reports (Buchanan, San Francisco Chronicle, 5/15). The state Assembly last Monday voted 48-29 in favor of a similar measure (A.B. 119). Insurance companies maintain that the practice, known as gender rating, is justified because younger women typically seek health care services more frequently than men. According to a report by the National Women"s Law Center, women can pay up to 20% more than men for the same individual coverage. Federal law already prohibits employers that offer health plans from charging different rates based on gender, and ten states have similar laws that apply to individual plans. However, the remaining 40 states allow the practice.State Sen. Mark Leno (D) authored the Senate legislation after San Francisco filed a lawsuit against the state seeking to outlaw gender rating. The lawsuit is on hold pending the outcome of the two bills (Buchanan, San Francisco Chronicle, 5/14).
News of the day
EPA Declares First-Ever Public Health Emergency In Montana
The Environmental Protection Agency on Wednesday declared its first-ever "public health emergency," asbestos contamination near Libby and Troy, Mont., northwestern mining towns, the Associated Press reports. "Asbestos contamination from a now-closed vermiculite mine has been cited in the deaths of more than 200 people and illnesses of thousands more. Before the vermiculite mine was closed in 1990, miners carried asbestos home on their clothes. Vermiculite once covered school running tracks in Libby and some residents used vermiculite as mulch in their home gardens."
Medical Devices

Study Rewrites Textbook On Key Genetic Phenomenon

Because females carry two copies of the X chromosome to males" one X and one Y, they harbor a potentially toxic double dose of the over 1000 genes that reside on the X chromosome. To compensate for this imbalance, mammals such as mice and humans shut down one entire X-chromosome through a phenomenon known as X-inactivation. For almost two decades, researchers have believed that one particular gene, called Xist, provides the molecular trigger of X-inactivation. Now, a new UNC study appearing online July 1 in the journal Nature disputes the current dogma by showing that this process can occur even in the absence of this gene. "Our study contradicts what is written in the textbooks," said senior study author Terry Magnuson, Ph.D., Sarah Graham Kenan Professor and chair of genetics, director of the Carolina Center for Genome Sciences and a member of the UNC Lineberger Comprehensive Cancer Center. "Everybody thought that Xist triggers X-inactivation, but now we have to rethink how this important process starts." Previous studies showed that the Xist gene was active or "turned on" early in the course of X-inactivation and that disruptions in the gene resulted in irregular X-inactivation, eventually leading to the accepted assumption that Xist was the trigger. But it wasn"t clear in the literature if this genetic phenomenon would initiate if Xist isn"t present, said lead study author Sundeep Kalantry, Ph.D., postdoctoral fellow in the UNC department of genetics. Kalantry used three different molecular techniques to look at X-inactivation in the embryos of mice that were genetically engineered to contain a defective Xist gene on their future inactive X-chromosome. He discovered that the genes on this X-chromosome could be silenced regardless of whether they produced Xist. But while Xist was not absolutely required to start X-inactivation, without it genes along the X-chromosome eventually became active again. Thus, Xist appears to stabilize silencing of the X-chromosome over the long term. Unlike most genes, the Xist gene doesn"t code for a protein. Rather, it acts at the level of RNA - a copy of the DNA genetic sequence - which serves to recruit protein complexes through a process known as epigenetics. These proteins then form a molecular scaffold along the inactive-X chromosome that can stably silence the genes contained within it. The UNC researchers are now actively investigating how this chromosomal remodeling begins in the first place. "If we can figure out the mechanism that triggers X-inactivation, we can potentially apply this knowledge to diseases that have an epigenetic component," Kalantry said. "So it can have implications not only in fundamentally understanding X-inactivation but also to gain insight into the increasing array of illnesses where the epigenetic machinery has gone awry such as in prostate and breast cancers." Along with Magnuson and Kalantry, study co-authors are Sonya Purushothaman, undergraduate student; Randall Bryant Bowen, research technician; and Joshua Starmer; Ph.D., postdoctoral fellow. The research was supported in part by the National Institutes of Health and by an American Cancer Society Postdoctoral Fellowship. University of North Carolina


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):